Clinical Application and Utility of PyLARIFY (18F DCFPyL) in Prostate Cancer Videos - Results from #10

Clinical Application and Utility of PyLARIFY (18F DCFPyL) in Prostate Cancer Videos

Search

F-18-Labeled DCFPyL in Patients With Metastatic Prostate Cancer Undergoing Treatment With ADT – Esther Mena Gonzalez Details In this presentation from Esther Mena Gonzalez, she discusses her team’s findings on the role of castration status or hormone-sensitive castrate-resistance data and androgen deprivation therapy (ADT) in the use of 18F DCFPyL PET/CT. She discussed the objective of her study to be to investigate the performance of 18F DCFPyL in her cohort of patients with documented metastatic prostate cancer who we...
18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen Details In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the Clinical Cancer Research publication on the results from the CONDOR Phase 3, multicenter study. In particular, conventional imaging performs poorly when PSA levels are low, less than 2 ng/mL, and the use of novel PET radiotracers may address this issue and provide more sensitive imaging. CONDOR was a prospective stu...
CONDOR: Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer - Michael J. Morris Details Michael Morris, Oliver Sartor, and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer. Correct localization rate (CLR), or the positive predictive value of the PyL scan, was established as the primary endpoint and the C...